Jin Rong Jie·2025-08-26 07:40Group 1 - The core viewpoint of the news is that the CSI 300 Pharmaceutical Index has shown significant growth, with a 10.82% increase over the past month, a 12.16% increase over the past three months, and a 23.32% increase year-to-date [1] - The CSI 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the CSI 300 Index, reflecting the overall performance of these companies [1] - The index was established on December 31, 2004, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the CSI 300 Pharmaceutical Index are: Heng Rui Medicine (44.62%), Pian Zai Huang (9.73%), Yunnan Baiyao (7.8%), Kelun Pharmaceutical (6.59%), East China Pharmaceutical (6.11%), New Harmony (5.67%), Fosun Pharmaceutical (5.58%), Baili Tianheng (3.99%), Tong Ren Tang (3.87%), and China Resources Sanjiu (3.11%) [1] - The market share of the CSI 300 Pharmaceutical Index holdings is 70.72% from the Shanghai Stock Exchange and 29.28% from the Shenzhen Stock Exchange [1] - The composition of the index holdings by industry shows that drug formulations account for 66.89%, traditional Chinese medicine accounts for 27.44%, and raw materials account for 5.67% [1] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the regular sample adjustments [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]